Mar 4, 2023 / Nov 16, 2024
YELLOW III
Effect of Evolocumab on Coronary Plaque Characteristics
Clinical Trial
This study aims to evaluate the impact of evolocumab on coronary plaque characteristics in patients with stable coronary artery disease (CAD) already on maximally tolerated statin therapy. Using intravascular imaging and PBMC gene expression analysis, the research integrates imaging techniques with machine learning-based transcriptomic analysis to identify molecular mechanisms driving beneficial changes in atherosclerotic plaques. The primary endpoints include changes in minimal fibrous cap thickness (FCT) measured by optical coherence tomography (OCT) and maxLCBI4mm assessed by near-infrared spectroscopy (NIRS) over 26 weeks of treatment. Secondary endpoints involve changes in lipid and macrophage-related plaque features assessed by OCT, plaque volume changes by intravascular ultrasound (IVUS), and PBMC gene expression profiles.
Part 1 – Imaging
Part 2 – Transcriptomic
Part 2 – Transcriptomic
Yellow III Transcriptomic Results Presentation
Yellow III In the News
Beyond the Data: YELLOW III: PCSK9 Inhibitors and Plaque Characterization
TCTMD – March 5, 2023
Clues to Evolocumab Response Exist in Patients’ Genes: YELLOW III
TCTMD – November 21, 2024
Stable CAD Plaque Morphology Improved by PCSK9 Inhibitors: YELLOW III
TCTMD – March 04, 2023
YELLOW III Study Improves Understanding of Evolocumab in CAD Treatment
HCPLive – March 05, 2023
ACC 23: Effect of Evolocumab on Coronary Plaque Morphology: The YELLOW III Study
ICRJournal – March 05 2023
Annapoorna Kini, ACC 2023: PCSK9 inhibitors for acute coronary syndrome
Touch Cardio – March 30 2023
Imaging data may predict best responders to evolocumab therapy: YELLOW III
Healio – March 04, 2023